Audentes Therapeutics Inc. | Key People and Executives
Matthew R. Patterson
Chief Executive Officer & Director
Jennifer Jarrett
Independent Director
Mark Alan Goldberg
Independent Director
Julie Anne Smith
Independent Director
Scott W. Morrison
Independent Director
Louis G. Lange
Independent Director
Thomas J. Schuetz
Independent Director
Kush M. Parmar
Independent Director
Natalie C. Holles
President & Chief Operating Officer
Matthew R. Patterson
Chief Executive Officer & Director
Thomas Paul Soloway
CFO, Principal Accounting Officer & Senior VP
John T. Gray
Chief Scientific Officer & Senior Vice President
Suyash Prasad
Chief Medical Officer & Senior Vice President
Fulvio Mavilio
Vice President-Scientific Affairs Europe Region
Paul Laland
Media Contact
Andrew H. Chang
Director-Investor Relations
David Nagler
Senior VP-Human Resources & Corporate Affairs
Mary Newman
Senior Vice President-Regulatory Affairs
Jennifer Jarrett
Independent Director
Mark Alan Goldberg
Independent Director
Julie Anne Smith
Independent Director
Scott W. Morrison
Independent Director
Louis G. Lange
Independent Director
Thomas J. Schuetz
Independent Director
Kush M. Parmar
Independent Director
| Address |
600 California Street
San Francisco California 94108
United States
|
|
Employees
|
- |
| Website |
http://www.audentestx.com |
| Updated |
07/08/2019 |
| Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. |
